Abstract. Relative changes in B-type natriuretic peptide (BNP) and amino terminal pro-BNP (NT-proBNP) levels may help to assess the risk of congestive heart failure (CHF). However, whether these levels at the time of admission enable the prediction of outcomes with acute exacerbation remains unknown. The current study determined the abilities of BNP, NT-proBNP and their ratio to predict in-hospital and long-term outcomes of patients with CHF. Patients who were admitted to the cardiac care unit of Juntendo University Hospital (Tokyo, Japan) with acute CHF onset were consecutively enrolled into the present observational study. Serum levels of BNP and NT-proBNP were immediately measured on admission, and other biomarkers and clinical data were also investigated. Of 195 enrolled patients, 16 (8.2%) succumbed to CHF in hospital and 124 (69.3%) reached the endpoint of mortality or readmission following a median follow-up of 14 months. Multiple linear regression analysis revealed body mass index, low density lipoprotein cholesterol, hemoglobin, estimated glomerular filtration rate and C-reactive protein as independent predictors of the NT-proBNP/BNP ratio. BNP, NT-proBNP and their ratio were significantly higher among those who succumbed to CHF than in those who remained alive in hospital (P<0.05). Logistic regression analysis indicated that the ratio was an independent predictor for in-hospital mortality and long-term outcomes. In conclusion, the ratio of NT-proBNP to BNP more effectively predicts in-hospital outcomes than either factor alone and it may also help to predict outcomes among patients with acute exacerbation of HF.
Introduction
Measurement of serum biomarkers including B-type natriuretic peptide (BNP) and amino terminal pro-BNP (NT-proBNP) has become important in evaluating the risk of congestive heart failure (CHF) (1) (2) (3) (4) (5) (6) . The 32-amino acid polypeptide BNP is secreted by cardiac myocytes in response to excessive distension and stretching of the cardiac wall and it has a half-life of ~20 min (range, 18-22 min) (7, 8) . The biologically inactive 76-amino acid N-terminal fragment NT-proBNP is co-secreted with BNP and it has a half-life of ~90 min (range, 60-120 min) (9, 10) . The diverse physiological effects of BNP include natriuresis and peripheral vasodilation, as well as inhibition of the renin-angiotensin-aldosterone and sympathetic nervous systems (11, 12) .
Understanding the level of BNP or NT-proBNP may provide an early diagnosis and guide for CHF therapy (1, 5, 13, 14) . The level of BNP and NT-proBNP at the time of discharge from hospital are important in the prediction of long-term outcomes among patients with CHF (4, 5) . However, the significance of BNP and NT-proBNP levels at the time of admission remains unknown. BNP and NT-proBNP were initially regarded as interchangeable parameters in CHF. However, this concept was challenged following the discovery that BNP and NT-proBNP are cleared and degraded differently (7, 9, 15, 16) . Furthermore, BNP and NT-proBNP are affected by other factors besides the severity of heart failure (HF), including obesity, renal function and inflammation (17) (18) (19) (20) . Differences between BNP and NT-proBNP in CHF assessment and the value of the NT-proBNP/BNP ratio remain unknown.
The present study aimed to determine which of these factors is the optimal marker of long-term CHF outcomes. The effects of a number of factors on the NT-proBNP/BNP ratio were analyzed and the predictive value of BNP was determined with regard to NT-proBNP and their ratios for short-and long-term outcomes of CHF. (13, 14) , history of ischemic heart disease, atrial fibrillation and hemodialysis were obtained from a review of medical records. Height and weight data was used to calculate the body mass index (BMI). Cardiac structure and function was determined following a standard echocardiography. The present study was performed according to the ethics policies of Juntendo University Hospital and was approved by the internal review board of the hospital.
End points. The end point for the short-term outcome was in-hospital mortality and for long-term outcomes was all-cause mortality and readmission. Follow-up ended in August 2010.
Laboratory measurements. Blood samples obtained from the patients immediately following admission to the CCU were sent to the clinical chemistry laboratory (Tokyo, Japan) and analyzed. Plasma BNP and NT-proBNP were analyzed using an AIA360 enzyme immunoassay analyzer (Tosho Corporation, Tokyo, Japan) and an electro-chemiluminescence immunoassay (cobas e411; Roche Diagnostics, Basel, Switzerland), respectively, according to the manufacturer's instructions. Statistical analysis. All variables were analyzed using the normal distribution test. Discrete variables are presented as frequency counts and ratios (%). Continuous variables are expressed as mean ± standard deviation when normally distributed, and otherwise as medians (inter-quartile range). Proportions and means/medians were compared using the χ 2 test, Student's t-test, one-way analysis of variance and the Mann-Whitney U test. Univariate correlations were tested in the context of normality using Pearson's correlation coefficient. Correlations among non-normally distributed variables were assessed using Spearman's rank correlation (ρ). Variables with a non-normal distribution were log-transformed prior to entry into the regression model. The results were statistically analyzed using JMP 8.0 software (SAS Institute Inc., Cary, NC, USA). All probabilities were two-tailed, and P<0.05 was considered to represent a statistically significant difference.
Results
Patient characteristics. The study population included 195 patients aged 65-80 years, with acute onset of HF. The patients' demographics, primary disease, cardiac function evaluation, clinical presentation and comorbidities are presented in Table I .
Factors affecting NT-proBNP/BNP ratio.
Multiple linear regression analysis demonstrated that BMI, low density lipoprotein cholesterol (LDL-C), hemoglobin (Hgb), eGFR and C-reactive protein (CRP) were independent predictors of the NT-proBNP/BNP ratio. Further univariate correlation analysis indicated that BNP, NT-proBNP and their ratios were significantly and negatively associated with BMI, Hgb and eGFR, and positively associated with CRP. These findings indicated that BMI, Hgb, eGFR and CPR affect NT-proBNP more than b n (%) and c mean ± standard deviation due to normal distribution. LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; BNP, B-type natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide; NT-proBNP/BNP, ratio of NT-proBNP to BNP; eGFR, estimated glomerular filtration rate; BMI, body mass index; Hgb, hemoglobin; LDL-C, low density lipoprotein cholesterol; CRP, C-reactive protein; DM, diabetes mellitus; HbA1c, glycated hemoglobin; Af, atrial fibrillation. BNP. A significant and negative association was identified between LDL-C and NT-proBNP/BNP, but not with either NT-proBNP or BNP (Table II) . with those who remained alive while in hospital (Fig. 1) . Logistic regression analysis including NT-proBNP/BNP, NT-proBNP and BNP indicated that the NT-proBNP/BNP ratio was the only independent predictor of in-hospital mortality (Table III) . The Kaplan-Meier survival curves for all-cause mortality and readmission are presented in Fig. 2 for BNP, NT-proBNP and the NT-proBNP/BNP ratio, respectively. Quartiles of NT-proBNP and the NT-proBNP/BNP ratio significantly differed (log-rank test, P= 0.018 and P= 0.0035, respectively), whereas those of BNP (log-rank test, P=0.21) did not. Cox proportional-hazard models of long-term outcomes including NT-proBNP/BNP, NT-proBNP and BNP indicated that the NT-proBNP/BNP ratio remained the only independent predictor of long-term outcomes (Table IV) . 
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Discussion
The present study demonstrated that the NT-proBNP/BNP ratio predicts the in-hospital and long-term outcomes of decompensated CHF more accurately than does the level of either BNP or NT-proBNP at the time of admission. The majority of previous studies (9,15,16) that have aimed to assess the predictive value of BNP and NT-proBNP were based Figure 2 . Kaplan-Meier survival curves for all-cause mortality and readmission stratified according to Q of (A) BNP, (B) NT-proBNP and (C) ratio of NT-proBNP to BNP. Red, green, blue and orange lines represent Q1, Q2, Q3 and Q4, respectively. Quartiles of NT-proBNP and NT-proBNP/BNP ratio (log-rank test, P= 0.018 and P= 0.0035, respectively) significantly differed, whereas those of BNP did not (log-rank test, P= 0.21). Q, quartiles; BNP, B-type natriuretic peptide; NT-proBNP, amino-terminal pro-B-type natriuretic peptide. Table III . Logistic regression analysis of in-hospital mortality of 16 patients. on data at the time of discharge, when these levels may be more stable than at the time of admission and reflect the basic and long-term ventricular status. However, an increase at the time of discharge provides more current information about exacerbation in acute HF. Therefore, the current study predicted in-hospital and long-term outcomes of CHF on the basis of the level of BNP and NT-proBNP upon admission. Cardiac myocytes synthesize proBNP that is then transformed into hormonally active BNP and inactive NT-proBNP. Although it is suggested that they are released from the heart in equimolar amounts, their half-lives and clearance pathways differ (7) (8) (9) . Plasma clearance of BNP is achieved via binding to natriuretic peptide receptor type C (NPR-C) and proteolysis by neutral endopeptidases, whereas NT-proBNP is primarily cleared by renal excretion (15, 16) . Exogenous atrial natriuretic peptide (ANP) has been applied as part of a treatment strategy for CHF (15) . Both ANP and BNP competitively bind to natriuretic peptide receptors but NT-proBNP does not. Nishiyama et al (20) reported that infused exogenous ANP (carperitide) influenced plasma BNP but not NT-proBNP. Therefore, plasma BNP and NT-proBNP are of similar relevance to the diagnosis and prognosis of HF but they are not equal and each has a different role in the assessment of HF due to different biological activities and sensitivities to pharmacological therapy.
Model includes NT-proBNP/BNP, Model includes NT-proBNP and BNP, adjusted adjusted ----------------------------------------------------------------------------------------------------------------------------------------------------------
According to the method of Jensen et al (21) , the current study assumed that BNP and NT-proBNP are produced at the same constant rate with a similar distribution volume in a one-compartment model, and that the production and elimination rates are equal. The calculated NT-proBNP/BNP ratio is 10.9, when the supposed half-lives of BNP and NT-proBNP are 20 and 90 min, respectively. However, the median value of the eNT-proBNP/BNP ratio in the present study was 8.7 (5.3-14.3), which was potentially due to differences in the influence of renal dysfunction on the elimination rate of NT-proBNP and BNP.
The mammalian natriuretic peptide system consists of the neurohormones, ANP, BNP, C-type natriuretic peptide (CNP) and NT-proBNP. ANP, BNP and CNP have a common 17-amino acid ring structure in which the majority of the amino acid residues are conserved. Atrial myocytes release stored 28-amino acid ANP in response to atrial distension and stretching (15, 16) . The physiological actions of ANP are similar to those of BNP, including a reduction in systemic vascular resistance and central venous pressure and an increase in natriuresis (22) . The ANP level has been demonstrated to be significant in the prognosis of patients with atrial fibrillation and CHF (23) (24) (25) . However, BNP and NT-BNP appear superior to ANP in the diagnosis of HF due to a closer association with echocardiographic evidence of left ventricular dysfunction and a longer half-life. Thus, the present study primarily focused on BNP and NT-proBNP to reflect ventricular status.
The present study demonstrated that the major factors affecting the NT-proBNP/BNP ratio included dystrophic status (BMI, LDL-C), anemia (Hgb), renal dysfunction (eGFR) and inflammation (CRP). Renal function (17, 18, 26, 27) , obesity (28) (29) (30) and inflammation (19, 21) are non-cardiac factors that should be considered during BNP and NT-proBNP evaluations.
The levels of BNP and NT-proBNP increase in patients with renal failure (16) . The clearance of NT-proBNP may be more reliant upon renal filtration and the levels may thus increase in response to renal failure to a greater extent than those of BNP, since BNP is also cleared by receptor-mediated Table IV . Cox proportional-hazard models of long-term outcomes. uptake and protease action; therefore, the NT-proBNP/BNP ratio would increase (31-33). Jensen et al (21) suggested that the increased NT-proBNP/BNP ratio is due to inflammation increasing the level of NT-proBNP more than that of BNP. Inflammation may increase BNP clearance mediated by protease or receptors, thus balancing the increase in BNP production. As NT-proBNP is not affected by these clearance mechanisms, NT-proBNP is elevated to a larger extent by inflammation, leading to an increased NT-proBNP/BNP ratio. The mechanism of different effects of dystrophic status and anemia on NT-proBNP and BNP remains unknown. However, changes in the level of NPR-C, receptor-mediated uptake and protease action in dystrophic and anemia status may be one explanation.
Model includes NT-proBNP/BNP, Model includes NT-proBNP and BNP, adjusted adjusted ------------------------------------------------------------------------------------------------------------------------------------------------------
Previous studies have primarily focused on the predictive value of NT-proBNP and BNP and both have been demonstrated to be predictors of CHF (9, 16) . However, each has advantages and disadvantages in predicting the outcomes of CHF: BNP has a shorter half life and may theoretically reflect more recent ventricular status, whereas NT-proBNP has greater stability and provides more information, but not regarding ventricular tension and function. Thus, the NT-proBNP/BNP ratio provides considerable information about parameters including renal dysfunction, nutrition status, anemia and inflammation, and may therefore serve as a new index in combination with other biomarkers. The NT-proBNP/BNP ratio may be a more useful and accurate predictor of CHF than single biomarkers.
Although the present study indicated some interesting results, there were also a few limitations. Firstly, the present study involved relatively small sample amounts. We would involve a larger patient sample in a further study. Secondly, the predictive function of the NT-proBNP to the BNP combining method has not been compared with the classical methods fully in a clinical setting. We will compare the present method with the classical methods in a further study.
In conclusion, the NT-proBNP/BNP ratio is an improved predictor of in-hospital and long-term outcomes of CHF, compared with BNP or NT-proBNP alone. The NT-proBNP/BNP ratio is negatively associated with Hgb, eGFR, BMI and positively with CRP, as each variable exerts different effects on NT-proBNP and BNP. Anemia, renal dysfunction, inflammation and dystrophic status affect NT-proBNP more than they affect BNP. Thus, the NT-proBNP/BNP ratio may be useful to predict the short-and long-term outcomes of patients with acute exacerbation of HF.
